Capstone Therapeutics (NASDAQ:CAPS) Shares Down 3.1% – Should You Sell?

Capstone Therapeutics Corp. (NASDAQ:CAPS)’s stock price traded down 3.1% during trading on Friday . The stock traded as low as $0.25 and last traded at $0.2564. Approximately 124,383 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 202,915 shares. The stock had previously closed at $0.2647.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, July 2nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Capstone Therapeutics Price Performance

The firm has a 50-day moving average of $0.31 and a 200-day moving average of $0.51. The stock has a market cap of $3.90 million, a PE ratio of -0.08 and a beta of -1.51. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.95 and a quick ratio of 0.29.

Capstone Therapeutics (NASDAQ:CAPS) last posted its quarterly earnings results on Wednesday, May 20th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The business had revenue of $12.64 million during the quarter, compared to the consensus estimate of $10.80 million. Capstone Therapeutics had a negative return on equity of 114.15% and a negative net margin of 41.26%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC purchased a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics at the end of the most recent quarter. 2.55% of the stock is currently owned by hedge funds and other institutional investors.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.